

Mohammed Saji Salahudeen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1979439/publications.pdf>

Version: 2024-02-01

38
papers

1,194
citations

623188

14
h-index

395343

33
g-index

41
all docs

41
docs citations

41
times ranked

1532
citing authors

#	ARTICLE	IF	CITATIONS
1	Eight-Year Trends in Direct-Acting Oral Anticoagulant Dosing, Based on Age and Kidney Function, in Patients With Atrial Fibrillation. <i>Journal of Patient Safety</i> , 2022, 18, 337-341.	0.7	2
2	Effectiveness of Interventions to Improve the Anticholinergic Prescribing Practice in Older Adults: A Systematic Review. <i>Journal of Clinical Medicine</i> , 2022, 11, 714.	1.0	8
3	Ten-year trends in adverse drug reaction-related hospitalizations among people with dementia. <i>Therapeutic Advances in Drug Safety</i> , 2022, 13, 204209862210807.	1.0	4
4	Oral Anticoagulant Treatment and the Risk of Dementia in Patients With Atrial Fibrillation: A Population-Based Cohort Study. <i>Journal of the American Heart Association</i> , 2022, 11, e023098.	1.6	18
5	Comparing the renal outcomes in patients with atrial fibrillation receiving different oral anticoagulants. <i>Expert Review of Clinical Pharmacology</i> , 2022, 15, 359-364.	1.3	2
6	Actual drug-related harms in residential aged care facilities: a narrative review. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 1047-1060.	1.0	1
7	Risk of osteoporosis in patients with atrial fibrillation with and without oral anticoagulant therapy. <i>Expert Review of Clinical Pharmacology</i> , 2022, 15, 1003-1010.	1.3	2
8	Outcomes of Medication Misadventure Among People With Cognitive Impairment or Dementia: A Systematic Review and Meta-analysis. <i>Annals of Pharmacotherapy</i> , 2021, 55, 530-542.	0.9	5
9	Factors influencing oral anticoagulant use in patients newly diagnosed with atrial fibrillation. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13457.	1.7	11
10	Ten-Year Trends in the Use of Oral Anticoagulants in Australian General Practice Patients With Atrial Fibrillation. <i>Frontiers in Pharmacology</i> , 2021, 12, 586370.	1.6	20
11	Pharmacist-led interventions to reduce adverse drug events in older people living in residential aged care facilities: A systematic review. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 3672-3689.	1.1	17
12	Stroke risk reassessment and oral anticoagulant initiation in primary care patients with atrial fibrillation: A ten-year follow-up. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13489.	1.7	11
13	Ten-year trends in prescribing of antiarrhythmic drugs in Australian primary care patients with atrial fibrillation. <i>Internal Medicine Journal</i> , 2021, 51, 1732-1735.	0.5	2
14	Drug-associated non-pyrogenic hyperthermia: a narrative review. <i>European Journal of Clinical Pharmacology</i> , 2020, 76, 9-16.	0.8	6
15	Drug-associated hyperthermia: A longitudinal analysis of hospital presentations. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2020, 45, 477-487.	0.7	2
16	Association between anticholinergic drug burden and mortality in older people: a systematic review. <i>European Journal of Clinical Pharmacology</i> , 2020, 76, 319-335.	0.8	31
17	Five-Year Trends in Potential Drug Interactions with Direct-Acting Oral Anticoagulants in Patients with Atrial Fibrillation: An Australian-Wide Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 3568.	1.0	14
18	Esketamine: new hope for the treatment of treatment-resistant depression? A narrative review. <i>Therapeutic Advances in Drug Safety</i> , 2020, 11, 204209862093789.	1.0	33

#	ARTICLE	IF	CITATIONS
19	Pharmacists as a Source of Advice on Medication Use for Athletes. <i>Pharmacy (Basel, Switzerland)</i> , 2020, 8, 10.	0.6	13
20	A Systematic Review Evaluating the Use of the interRAI Home Care Instrument in Research for Older People. <i>Clinical Gerontologist</i> , 2019, 42, 463-484.	1.2	17
21	A review of current evidence allied to step-up and top-down medication therapy in inflammatory bowel disease. <i>Drugs of Today</i> , 2019, 55, 385.	0.7	6
22	Study on the Classification, Causality, Preventability and Severity of Adverse Drug Reaction Using Spontaneous Reporting System in Hospitalized Patients. <i>Pharmacy (Basel, Switzerland)</i> , 2018, 6, 108.	0.6	25
23	Deprescribing medications in older people: a narrative review. <i>Drugs of Today</i> , 2018, 54, 489.	0.7	14
24	An overview of pharmacodynamic modelling, ligand-binding approach and its application in clinical practice. <i>Saudi Pharmaceutical Journal</i> , 2017, 25, 165-175.	1.2	108
25	An overview of pharmacoepidemiology in New Zealand: medical databases, registries and research achievements. <i>New Zealand Medical Journal</i> , 2017, 130, 52-61.	0.5	2
26	Cognitive adverse effects and brain deterioration associated with use of anticholinergic activity medicines in older adults. <i>Evidence-Based Medicine</i> , 2016, 21, 235-235.	0.6	2
27	Examination and Estimation of Anticholinergic Burden: Current Trends and Implications for Future Research. <i>Drugs and Aging</i> , 2016, 33, 305-313.	1.3	23
28	Temporal trends in the use of antidiabetic medicines: a nationwide 9-year study in older people living in New Zealand. <i>Therapeutic Advances in Drug Safety</i> , 2016, 7, 184-194.	1.0	2
29	Residential medication management reviews of antithrombotic therapy in aged care residents with atrial fibrillation: assessment of stroke and bleeding risk. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2016, 41, 279-284.	0.7	10
30	Anticholinergics: theoretical and clinical overview. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 753-768.	1.0	103
31	Serum Anticholinergic Activity and Cognitive and Functional Adverse Outcomes in Older People: A Systematic Review and Meta-Analysis of the Literature. <i>PLoS ONE</i> , 2016, 11, e0151084.	1.1	38
32	Credentials for a PharmD graduate: The voyage never ends. <i>SAGE Open Medicine</i> , 2015, 3, 205031211558422.	0.7	4
33	The Influence of Patient Characteristics on Anticholinergic Events in Older People. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2015, 5, 530-541.	0.6	19
34	Temporal Trends in Polypharmacy and Hyperpolypharmacy in Older New Zealanders over a 9-Year Period: 2005-2013. <i>Gerontology</i> , 2015, 61, 195-202.	1.4	80
35	Comparison of Anticholinergic Risk Scales and Associations with Adverse Health Outcomes in Older People. <i>Journal of the American Geriatrics Society</i> , 2015, 63, 85-90.	1.3	134
36	Anticholinergic burden quantified by anticholinergic risk scales and adverse outcomes in older people: a systematic review. <i>BMC Geriatrics</i> , 2015, 15, 31.	1.1	358

#	ARTICLE	IF	CITATIONS
37	Impact of Anticholinergic Discontinuation on Cognitive Outcomes in Older People: A Systematic Review. <i>Drugs and Aging</i> , 2014, 31, 185-192.	1.3	36
38	A study of the factors affecting time to onset of lactogenesis-II after parturition. <i>Journal of Pharmacy Research</i> , 2013, 6, 68-72.	0.4	9